secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2024-08-15T23:59:59+00:00
Accession:  0001104659-24-089913
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio Q2 net loss $0.44/share; cash $12.1M; AD & PD trial data positive
-----------------------------------------------------------------------------

- Q2 2024 net loss $0.44 per share vs $1.07 YoY; operating expenses $7.8M (R&D $5.8M, G&A $2.0M).
- Cash $4.0M at June 30, 2024; increased to $12.1M as of Aug 14 via warrant exercises and ELOC.
- Phase 2/3 AD study: 3.3-point ADAS-Cog11 improvement vs 0.3 placebo; effective in APOE4 carriers; no ARIA.
- Phase 3 PD study: improvements in MDS-UPDRS and cognition; halted cognitive decline in all patients.
- New crystalline buntanetap patent filed; FDA OK for phase 3 with crystal form; US patent for TBI; team expanded.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924089913/0001104659-24-089913-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924089913/tm2421776d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-089913

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer